Dr Lal Path Labs Limited completes Anchor Allocation

Dr Lal Path Labs Limited(Dr Lal) which is tapping the capital markets with its offer for sale of 1.16 cr shares completed allocation to anchor investors yesterday. The company allotted 34.80 lac shares at the top end of the band at Rs550to 15 anchor investors comprising of 26 entities. The list includes many well known names and is fairly exhaustive. The issue which has a price band of Rs540-550, opens today and closes on Thursday the 10th of December.

It’s probably after a long time that one is likely to see a liquidity crunch with two large issues running simultaneously, a tax free bond issue opening on the same day coupled with advance tax due on the 15th of December. All this put together would squeeze the leveraged investor and make him pay more for the rupee that he borrows. This would also significantly increase the cost of borrowing for the HNI’s who would be applying in the issues of Dr Lal and Alkem Laboratories which would be raising roughly Rs 2,000 crs.

The full list of anchor investors and entities is given below:-

chart2

Alkem Laboratories Limited completes Anchor Allocation

Alkem Laboratories Limited which is tapping the capital markets with its offer for sale of 128.53 lac shares completed allocation to anchor investors yesterday. The company allotted 37,66,358 shares at the top end of the band at Rs 1,050 to 25 anchor investors comprising of 47 entities. The list includes almost all the local funds and a host of international ones. The issue which has a price band of Rs 1020-1050, opens today and closes on Thursday the 10th of December.

chart

Stray thoughts on Monday

The benchmark indices saw the BSESENSEX lose 1.88% and NIFTY 2.02%. While global cues were weak, for once marketmen could not blame parliament as it functioned near normal. GST bill has been slated for discussion and the possibility of this mammoth legislation and a key reform is quite likely to get the nod from Rajya Sabha. The market has been sensing this and reacting accordingly. FII’s have continued to be sellers and whether it is year-end realignment or the anticipated rate hike by the FED, one is not sure. Their selling is affecting the large cap stocks which are under pressure and the converse is happening in the midcap and smallcap stocks which are rising. These stocks are being bought by domestic institutions which are receiving money in these funds only.

This is a cautionary signal and investors need to take care of the same. Action is shifting this week to the primary market where two issues are opening. They are from Dr Lal Path Labs Limited and Alkem Laboratories Limited. Both are secondary issues where no money being raised would go to the company and would only go to the selling shareholders.

Dr Lal Path Labs Limited is issuing 1.16 cr shares in a price band of Rs 540 and 550. The issue would raise Rs 626.4 crs to 638 crs and the PE at the upper band is a staggering 47.91 times based on FY15 consolidated basis. The 2 merchant bankers of the issue have handled 10 issues in the last three years of which 6 were below par on listing day. The issue opens on Tuesday the 8th December and closes on Thursday the 10th December.

Alkem Laboratories Limited is issuing 1,28,53,442 shares in a price band of Rs 1,020-1,050. The issue would raise Rs 1,311 crs to Rs 1,349 crs. The PE based on consolidated numbers for year ended March 2015 is between 26.4 to 27.1 times. The 4 merchant bankers of the issue have handled 12 issues in the last three years of which 4 were below issue price on listing day. The issue opens on Tuesday the 8th of December and closes on Thursday the 10th of December.There is a corrigendum to the RHP of Alkem today of a penalty imposed by CCI (Competition Commission of India) of Rs 74.63 crs. The company has a right to appeal for the same but it would have under prudent accounting have to make a contingent liability for the same.

The anchor portion for both issues is slated for Monday the 7th of December. The grey market is quite active with a premium in the range of 20% for both issues.

One or two more issues are expected in the remaining days of the current calendar year as there is apprehension in the minds of promoters and merchant bankers about compulsory ASBA for retail investors being introduced from 1st January 2016. This spurt in primary market activity is primarily on account of this reason.

SEBI chief has put it on record that he is quite happy if retail investors do not come to the primary market or the secondary market directly but came via institutions or mutual funds. The government has launched a massive financial inclusion programme called Jan DhanYojana. One wonders whether people concerned are aware that SEBI which is an institution under the very own Finance ministry is running a programme which is completely the opposite of what the government wants. Strange are the ways things happen in India.
May God save us retail investors?

Subscribe to RSS Feed Follow me on Twitter!